Cargando…

Genetic variants as predictors of toxicity and response in patients with non‐small cell lung cancer undergoing first‐line platinum‐based chemotherapy: Design of the multicenter PGxLUNG study

INTRODUCTION: Platinum–based chemotherapy is currently the most frequently applied first‐line treatment for patients with advanced non‐small cell lung cancer (NSCLC) without targetable mutations or high PD‐L1 expression. Unfortunately, chemotherapy‐induced toxicity is prevalent and may affect patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Jong, Corine, Herder, Gerarda J.M., Deneer, Vera H.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705630/ https://www.ncbi.nlm.nih.gov/pubmed/33073546 http://dx.doi.org/10.1111/1759-7714.13683

Ejemplares similares

Association between serum biomarkers CEA and LDH and response in advanced non‐small cell lung cancer patients treated with platinum‐based chemotherapy
por: de Jong, Corine, et al.
Publicado: (2020)

The association between skeletal muscle measures and chemotherapy‐induced toxicity in non‐small cell lung cancer patients
por: de Jong, Corine, et al.
Publicado: (2022)

Association between Genetic Variants and Peripheral Neuropathy in Patients with NSCLC Treated with First-Line Platinum-Based Therapy
por: de Jong, Corine, et al.
Publicado: (2023)

Pharmacogenomic (PGx) Counseling: Exploring Participant Questions about PGx Test Results
por: Schmidlen, Tara, et al.
Publicado: (2020)

PGx: Putting Peptides to BED
por: Askenazi, Manor, et al.
Publicado: (2015)

PGxO and PGxLOD: a reconciliation of pharmacogenomic knowledge of various provenances, enabling further comparison
por: Monnin, Pierre, et al.
Publicado: (2019)

Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
por: Spasic, Jelena, et al.
Publicado: (2022)

WISP1 Polymorphisms Contribute to Platinum-Based Chemotherapy Toxicity in Lung Cancer Patients
por: Chen, Juan, et al.
Publicado: (2014)

HUGO Statement on Pharmacogenomics (PGx): Solidarity, Equity and Governance
Publicado: (2007)

PGxCorpus, a manually annotated corpus for pharmacogenomics
por: Legrand, Joël, et al.
Publicado: (2020)

PGxMine: Text mining for curation of PharmGKB
por: Lever, Jake, et al.
Publicado: (2020)

Drug Use among Nursing Home Residents in Denmark for Drugs Having Pharmacogenomics Based (PGx) Dosing Guidelines: Potential for Preemptive PGx Testing
por: Vermehren, Charlotte, et al.
Publicado: (2020)

Pharmacogenomics (PGx) Patient with Mixed Levels of Actionable Variant Evidence
por: Schuh, Michael J., et al.
Publicado: (2020)

Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation
por: Hiratsuka, Masahiro, et al.
Publicado: (2021)

Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy
por: Ying, Jun, et al.
Publicado: (2019)

Genetic Polymorphisms and Platinum-Based Chemotherapy-Induced Toxicities in Patients With Lung Cancer: A Systematic Review and Meta-Analysis
por: Liu, Wenhui, et al.
Publicado: (2020)

Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
por: Hisakane, Kakeru, et al.
Publicado: (2023)

Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
por: Yamashita, Fumie, et al.
Publicado: (2013)

Effects of PGX, a novel functional fibre, on acute and delayed postprandial glycaemia
por: Brand-Miller, J C, et al.
Publicado: (2010)

Potential Benefits of Pre-emptive PGx Testing in Male Breast Cancer Patients
por: Randles, Heather H., et al.
Publicado: (2019)

Population Pharmacogenomics in Croatia: Evaluating the PGx Allele Frequency and the Impact of Treatment Efficiency
por: Matišić, Vid, et al.
Publicado: (2023)

Effect of XPD and TP53 Gene Polymorphisms on the Risk of Platinum-Based Chemotherapy Induced Toxicity in Bangladeshi Lung Cancer Patients
por: Nairuz, Tahsin, et al.
Publicado: (2021)

Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma
por: Zhai, Xiaoyu, et al.
Publicado: (2017)

Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma
por: Wang, Yuli, et al.
Publicado: (2018)

Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy
por: Liu, Jia-Si, et al.
Publicado: (2023)

Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer
por: Thatcher, N, et al.
Publicado: (1999)

Association between DNA mismatch repair gene polymorphisms and platinum-based chemotherapy toxicity in non-small cell lung cancer patients
por: Liu, Jun-Yan, et al.
Publicado: (2017)

Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients
por: Cui, Jia-Jia, et al.
Publicado: (2017)

Polygalacturonase gene pgxB in Aspergillus niger is a virulence factor in apple fruit
por: Liu, Cheng-Qian, et al.
Publicado: (2017)

PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics
por: Zubiaur, Pablo, et al.
Publicado: (2021)

Pharmacogenomics polygenic risk score for drug response prediction using PRS-PGx methods
por: Zhai, Song, et al.
Publicado: (2022)

The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy
por: Zhou, Fei, et al.
Publicado: (2013)

Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer
por: Shiozawa, Toshihiro, et al.
Publicado: (2018)

The Effects of WISP1 Polymorphisms on the Prognosis of Lung Cancer Patients with Platinum-Based Chemotherapy
por: He, Jia, et al.
Publicado: (2021)

Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Puskas, Rita, et al.
Publicado: (2021)

The safety of PolyGlycopleX(® )(PGX(®)) as shown in a 90-day rodent feeding study
por: Matulka, Ray A, et al.
Publicado: (2009)

Correction: Polygalacturonase gene pgxB in Aspergillus niger is a virulence factor in apple fruit
por: Liu, Cheng-Qian, et al.
Publicado: (2018)

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
por: Ramalingam, Suresh S., et al.
Publicado: (2021)

Performance and Prospects of [(68)Ga]Ga-FAPI PET/CT Scans in Lung Cancer
por: Borgonje, Paula E., et al.
Publicado: (2022)

Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy
por: Kaewbubpa, Walennee, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7ag6aiohj6pqnjbl8g6ojlafok